43 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in Jul 2030. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
1
Ending by 2030
Jul 2030
Next term end
35
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Mar 2041 · High confidence
Also notable
Ends Jan 2043 · High confidence
Also notable
Ends May 2038 · High confidence
Systems and Methods for Creating Enhanced Documents for Perfect Automated Parsing
US 11,537,727
Cited by 9 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2041.
Systems and Methods for Improved User-Reviewer Interaction Using Enhanced Electronic Documents Linked to Online Documents
US 11,775,754
Cited by 5 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2043.
Manufacture of TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE (III)] and Compositions Thereof
US 10,611,787
A family of 5 related applications built on the 2020 grant. Protection runs to 2038.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 28, 2027The maintenance fee for Manufacture of TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE (III)] and Compositions Thereof (US 11,739,111) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
- 1 fee due Apr 3, 2027The maintenance fee for Systems and Methods for Improved User-Reviewer Interaction Using Enhanced Electronic Documents Linked to Online Documents (US 11,775,754) comes due Apr 3, 2027. Unpaid by Oct 4, 2027, it lapses early.
- 1 fee due Jul 30, 2027The maintenance fee for Adaptive Autofill Systems and Methods (US 11,886,802) comes due Jul 30, 2027. Unpaid by Jan 31, 2028, it lapses early.
- 1 fee due Oct 7, 2027The maintenance fee for Manufacture of TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE (III)] and Compositions Thereof (US 10,611,787) comes due Oct 7, 2027. Unpaid by Apr 7, 2028, it lapses early.
Recent changes
- 5 of the patents on this record were granted since Aug 16, 2026
What they patent
The 5 largest of its 35 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Systems and Methods for Creating Enhanced Documents for Perfect Automated Parsing | 4 in force | to Mar 2041 |
| Manufacture of TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE (III)] and Compositions Thereof | 4 in force | to May 2038 |
| Systems and Methods for Improved User-Reviewer Interaction Using Enhanced Electronic Documents | 2 in force | to Feb 2042 |
| Display Screen or Portion Thereof with Graphical User Interface | 2 in force | to May 2041 |
| Multi-Signal Learning System | 1 in force | to May 2044 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US D762,231 | Display Screen or Portion Thereof with Graphical User Interface In force · High confidence | In force | High confidence | |
| US 8,952,251 | High-Capacity/Efficiency Transmission Line Design held by Bold Transmission, LLC In force · High confidence | In force | High confidence | |
| US 11,633,380 | Use of TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE(III)] for the Treatment of Cancer held by Bold Therapeutics, Inc. In force · Low confidence | In force | Low confidence | |
| US 10,611,787 | Manufacture of TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE (III)] and Compositions Thereof held by Bold Therapeutics, Inc. In force · High confidence | In force | High confidence | |
| US 11,040,993 | Manufacture of TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE (III)] and Compositions Thereof held by Bold Therapeutics, Inc. In force · High confidence | In force | High confidence | |
| US 11,739,111 | Manufacture of TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE (III)] and Compositions Thereof held by Bold Therapeutics, Inc. In force · High confidence | In force | High confidence | |
| US 12,415,825 | Manufacture of TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE (III)] and Compositions Thereof held by Bold Therapeutics, Inc. In force · High confidence | In force | High confidence | |
| US D1,077,849 | Display Screen with Graphical User Interface In force · High confidence | In force | High confidence | |
| US 11,886,802 | Adaptive Autofill Systems and Methods In force · High confidence | In force | High confidence | |
| US D1,089,245 | Display Screen with Graphical User Interface In force · High confidence | In force | High confidence |
Also on record, not counted in the 43: 32 applications pending · 4 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.